-
Mashup Score: 3TP-3654 Monotherapy Well-tolerated in Relapsed or Refractory Myelofibrosis | Blood Cancers Today - 2 month(s) ago
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6EBMT, ELN Working Group Publish Updated Guidelines for HSCT in Myelofibrosis | Blood Cancers Today - 2 month(s) ago
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Combination Therapy Demonstrates ‘Potential Disease-Modifying Activity’ in Myelofibrosis | Blood Cancers Today - 2 month(s) ago
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with JAKi-naïve myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Adding Parsaclisib to Ruxolitinib Improves Myelofibrosis Symptoms and Spleen Volume | Blood Cancers Today - 2 month(s) ago
Adding parsaclisib to ruxolitinib can improve symptoms and spleen volume in patients with myelofibrosis who do not respond optimally to ruxolitinib therapy alone.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
A mouse study suggests that platelet factor 4 (PF4) derived from megakaryocytes, cells that are known to promote inflammation, plays a critical role in the progression of MPNs.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Myelofibrosis Takes Toll on Quality of Life | Blood Cancers Today - 2 month(s) ago
Patients with early-stage myelofibrosis suffer less damage to quality of life compared with those who have overt disease, but they nevertheless have a high prevalence of symptoms.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
The JAK2/IRAK1/ACVR1 inhibitor pacritinib may not only stabilize platelet (PLT) counts but also boost them in some patients with cytopenic myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Ropeginterferon Alfa-2b Is an Effective Treatment for Prefibrotic Primary Myelofibrosis | Blood Cancers Today - 2 month(s) ago
Researchers assessed 66 patients with confirmed prefibrotic primary myelofibrosis (pre-PMF), overt PMF, post-polycythemia vera MF, or post-essential thrombocythemia MF.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3ATG Is an Effective Graft-Versus-Host Disease (GVHD) Prophylaxis in Patients with Myelofibrosis | Blood Cancers Today - 2 month(s) ago
Multivariable modeling showed a notable reduction in the risk of graft-versus-host disease (GVHD) or relapse in the antithymocyte/antilymphocyte globulin (ATG) group.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 16Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy - 3 month(s) ago
Anemia correlates with an increased risk of evolution into BP, both when present at baseline and when acquired during ruxolitinib monotherapy. Innovative anemia therapies and disease-modifying agents…
Categories: General Medicine News, Onc News and JournalsTweet
🙌 ICYMI: Spleen volume reduction was seen in patients with relapsed or refractory #myelofibrosis receiving TP-3654 monotherapy, according to a study led by @LindsayReinMD of @DukeHealth/@DukeCancer. 📰 Read more: https://t.co/QDwsIkVsY1 https://t.co/MKVuK2TOah